For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not associated with an increased risk for exacerbations, according to a study ...

Study results suggest immune checkpoint inhibitor therapy may offer immunomodulatory benefits for patients with asthma and ...

Among patients with asthma without diabetes, the risk for exacerbation was decreased with GLP-1 receptor agonist exposure, ...

Please provide your email address to receive an email when new articles are posted on . Global Initiative for Asthma (GINA) guidelines recommend single maintenance and reliever therapy (SMART) for ...

Breathing can feel normal for weeks, then suddenly turn into a race for air. That uncertainty is one of the hardest parts of living with asthma. Even when symptoms seem quiet, an attack can still ...

Only 15% of patients were adherent to ICS therapy 3 months after their asthma exacerbation, and less that one-fourth of those remained adherent 9 months later. Improved adherence to inhaled ...

Dupilumab shows long-term efficacy across yearly seasons in patients with type 2 inflammatory asthma. Patients with type 2 inflammatory asthma, with and without evidence of allergic asthma, ...

Underlying mood and sleep disorders may negatively affect asthma control, researchers find. “Asthma control, sleep quality, and mood are all critical factors in affecting an individual’s overall ...

MILWAUKEE, Feb. 15, 2026 /PRNewswire/ -- Glucagon-like peptide-1 receptor agonists (GLP-1) is linked to a significant reduction in asthma exacerbations for overweight, obese and morbidly obese ...

"The magnitude of the reduction in asthma exacerbations was large and clinically very meaningful. We were also surprised by the extent to which measures of urban stress appeared to mediate the link ...

Researchers reported on trends in the incidence and prevalence of pediatric asthma from 2008 to 2018 in the United Kingdom. Exacerbation rates in children with asthma in the UK increased by ...

September 25, 2012 (Vienna, Austria) — There is still no cure for the common cold, but interferon-β significantly decreases the frequency of cold-induced exacerbations in people with ...